China
Medical Device Regulation in China (NMPA)
Registration, Classification, and Market Entry Requirements
China is one of the largest and fastest-growing medical device markets in the world. However, it is also one of the most complex from a regulatory standpoint.
Market entry requires careful planning, significant documentation, and a clear understanding of local regulatory expectations—including testing, clinical evaluation, and quality system compliance.
Regulatory Authority
Medical devices in China are regulated by the National Medical Products Administration (NMPA). The NMPA is responsible for device classification, product registration and approvals, quality system oversight, and post-market surveillance and enforcement.
Provincial authorities may also play a role in registration and inspection activities.
Regulatory Framework
China’s system is risk-based, documentation-intensive, highly structured, and dependent on local requirements. Devices must be filed or registered with NMPA before they can be marketed in China.
Device Classification System
China uses a three-class system for device risk. The risk classification determines a device’s registration pathway, documentation requirements, and clinical expectations.
| Class | Risk Level | Examples |
| Class I | Low | Low-risk, non-invasive devices |
| Class II | Moderate | Diagnostic devices, infusion equipment |
| Class III | High | Implantable or life-supporting devices |
Market Authorization Pathways
Class I – Filing (Recordation)
The Class I recordation process is a simplified filing process with no full technical review and is managed at the provincial level. It is the fastest and least burdensome of the two China regulatory pathways.
Class II and III – Registration
The registration process requires a full regulatory submission with detailed technical and clinical documentation. Class II device submissions are reviewed by provincial authorities, and submissions for Class III devices are reviewed by the NMPA.
Key Requirements for Foreign Manufacturers
China imposes several requirements that differ significantly from other markets.
Local Agent Requirement
Foreign manufacturers must appoint a local Legal Agent in China, whose responsibilities include managing submissions, communicating with the NMPA, and supporting post-market compliance. This is a critical strategic relationship.
Type Testing in China (CRITICAL)
In most cases, devices must undergo type testing at an NMPA-designated laboratory that includes product testing against Chinese standards. Test reports are submitted as a part of registration. This is one of the most significant differences from other regulatory systems
Clinical Evaluation Requirements
Depending on device type, clinical trials may be required in China. Although some devices may qualify for clinical evaluation exemptions and the ability to use existing clinical data. In considering this, determining the correct pathway is essential to avoid delays.
Quality System Requirements
China requires compliance with NMPA Good Manufacturing Practice (GMP) requirements. Their GMP is similar in structure to ISO 13485 with China-specific expectations. Compliance may involve on-site inspections and documentation reviews. The 2014 China GMP will be superseded by its new GMP, effective in November 2026.
Technical Documentation Requirements
Registration dossiers typically include device description and intended use, risk analysis and classification rationale, type testing reports (China-based), clinical evaluation or trial data, labeling and instructions for use, and quality system documentation. All documentation must be submitted in Chinese.
Labeling Requirements
Medical devices in China must include Chinese-language labeling, product specifications and intended use, manufacturer and agent information, and instructions for use. Labeling must align strictly with approved registration content.
Post-Market Requirements
China has an increasingly active post-market surveillance system.
After a product enters the China market, manufacturers and local agents must comply with adverse event reporting, complaint handling, recall procedures, and ongoing regulatory compliance.
China vs Other Global Markets (Quick Comparison)
| Topic | China (NMPA) | United States | Canada |
| Market Authorization | Registration | 510(k), PMA | MDL |
| Local Representative | Required | Not required | Importer / MDEL |
| Testing | Local type testing required | Not typically required | Not required |
| Clinical Data | Often required locally | Varies | Varies |
| Quality System | NMPA GMP | QMSR / ISO 13485 | MDSAP required |
| Language | Chinese | English | English/French |
Why China Is a Strategic Market
China offers a large and growing healthcare market, significant commercial opportunity, and increasing demand for advanced medical technologies. However, regulatory complexity is high, timelines can be long, and local requirements are strict.
In general, entering the Chinese market is best approached as a strategic, planned expansion and not an opportunistic entry. Early planning is essential.
Key Challenges in China
Manufacturers commonly face local testing requirements, language and translation barriers, complex documentation expectations, clinical data requirements, and regulatory process variability.
Conclusion
China is a high value but complex regulatory environment. Successful market entry requires a structured approach, strong local partnerships, and a clear understanding of regulatory expectations. With the right strategy, China can be a powerful component of a global medical device commercialization plan.